Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes

Genes Chromosomes and Cancer

Volumn 46, Issue 4, 2007, Pages 373-384

  Narayan, Gopeshwar ^a   Bourdon, Veronique ^b   Chaganti, Seeta ^b   Arias Pulido, Hugo ^c,d   Nandula, Sobhadra V ^a   Rao, Pulivarthi H ^e   Gissmann, Lutz ^f   Dürst, Matthias ^g   Schneider, Achim ^h   Pothuri, Bhavana ^a   Mansukhani, Mahesh ^a   Basso, Katia ^a   Chaganti, R S K ^b   Murty, Vundavalli V ^a  

^a NewYork Presbyterian Hospital   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Instituto Nacional de Cancerología   (Colombia)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA;

ABCC3 GENE; AIM2 GENE; AKT1 GENE; AMPLICON; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CDCA8 GENE; CENTD3 GENE; CHROMOSOME 11Q; CHROMOSOME 20Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CSAG2 GENE; EPHB2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HRASLS GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIF4A GENE; LIG1 GENE; MICROARRAY ANALYSIS; MMP1 GENE; MMP13 GENE; MUC4 GENE; PRIORITY JOURNAL; PTK2 GENE; RECQL4 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RFC4 GENE; SKP2 GENE; SMARCA4 GENE; SMCIL1 GENE; TMSNB GENE; UBE2C GENE; UTERINE CERVIX CANCER;

CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 33947101323     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20418     Document Type: Article

References (37)

1. Albertson DG, Collins C, McCormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nat Genet 34:369-376.
2. Atkin NB. 1997. Cytogeneties of carcinoma of the cervix uteri: a review. Cancer Genet Cytogenet 95:33-39.
3. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM. 2005. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11:7012-7022.
4. Bourdon V, Naef F, Rao PH, Reuter V, Mok SC, Bosl GJ, Koul S, Murty VV, Kucherlapati RS, Chaganti RS. 2002. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res 62:6218-6223.
5. Califano A. 2000. SPLASH: Structural pattern localization analysis by sequential histograms. Bioinformatics 16:341-357.
6. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20.
7. Chatterjee A, Pulido HA, Koul S, Beleno N, Perilla A, Posso H, Manusukhani M, Murty VV. 2001. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: Occurrence of allelic deletions in precancerous lesions. Cancer Res 61:2119-2123.
8. Ellison V, Stillman B. 2003. Biochemical characterization of DNA damage checkpoint complexes: Clamp loader and clamp complexes with specificity for 5′ recessed DNA. PLoS Biol 1:E33.
9. Fitzpatrick MA, Funk MC, Gius D, Huettner PC, Zhang Z, Bidder M, Ma D, Powell MA, Rader JS. 2006. Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data. Gynecol Oncol 103:458-462.
10. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH. 2003. Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer 36:233-241.
11. Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G, Ried T. 1996. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 93:479-484.
12. Heselmeyer-Haddad K, Janz V, Castle PE, Chaudhri N, White N, Wilber K, Morrison LE, Auer G, Burroughs FH, Sherman ME, Ried T. 2003. Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 163:1405-1416.
13. Hickson ID. 2003. RecQ helicases: Caretakers of the genome. Nat Rev Cancer 3:169-178.
14. Hidalgo A, Baudis M, Petersen I, Arreola H, Pina P, Vazquez-Ortiz G, Hernandez D, Gonzalez J, Lazos M, Lopez R, Perez C, Garcia J, Vazquez K, Alatorre B, Salcedo M. 2005. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 5:77.
15. Hodgson JG, Chin K, Collins C, Gray JW. 2003. Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat 78:337-345.
16. Jonckheere N, Perrais M, Mariette C, Batra SK, Aubert JP, Pigny P, Van Seuningen I. 2004. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-β in pancreatic carcinogenesis. Oncogene 23:5729-5738.
17. Kersemaekers AM, van de Vijver MJ, Renter GG, Fleuren GJ. 1999. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer 26:346-354.
18. Lopez-Ferrer A, Alameda F, Barranco C, Garrido M, de Bolos C. 2001. MUC4 expression is increased in dysplastic cervical disorders. Hum Pathol 32:1197-1202.
19. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. 2000. PIK3CA as an oncogene in cervical cancer. Oncogene 19:2739-2744.
20. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. 2005. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 5:505-515.
21. Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS. 1994a. Allelotype analysis of cervical carcinoma. Cancer Res 54:4481-4487.
22. Mitra AB, Murty VV, Pratap M, Sodhani P, Chaganti RS. 1994b. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54:637-639.
23. Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB, Klinger HP. 1996. Genomic alterations in cervical carcinoma: Losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res 56:197-205.
24. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV. 2003a. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome. Mol Cancer 2:24.
25. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, Rao PH, Murty VV. 2003b. Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 22:3489-3499.
26. Overall CM, Lopez-Otin C. 2002. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2:657-6572.
27. Pollack JR, Perou CM, Alizadeti AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. 1999. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41-46.
28. Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleno N, Martinez G, Posso H, Evans GA, Murty VV. 2000. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 60:6677-6682.
29. Rader JS, Kamarasova T, Huettner PC, Li L, Li Y, Gerhard DS. 1996. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene 13:2737-2741.
30. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty W. 2004. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4:5.
31. Redon R, Hussenet T, Bour G, Caulee K, Jost B, Muller D, Abecassis J, du Manoir S. 2002. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res 62:6211-6217.
32. Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Jr., Pecorelli S. 2005. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: Identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 331:269-2691.
33. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. 2004. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 64:622-630.
34. Sozzi G, Huebner K, Croce CM. 1998. FHIT in human cancer. Adv Cancer Res 74:141-166.
35. Sugita M, Tanaka N, Davidson S, Sekiya S, Varella-Garcia M, West J, Drabkin HA, Gemmill RM. 2000. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet 117:9-18.
36. Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM. 2004. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23:6621-6629.
37. Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F, Zetterberg A, Wallin KL. 2002. Genetic alterations in cervical carcinomas: Frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 101:427-433.